Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Sept 2015

Ben-Baruch Noa Efrat, Bose Ron, Kavuri Shyam M, Ma Cynthia X, Ellis Matthew J

Abstract excerpt

Activating mutations in the HER2 tyrosine kinase have been identified in human breast cancers that lack HER2 gene amplification. These patients are not candidates for HER2-targeted drugs under current standards of care, but preclinical data strongly suggest that these patients will benefit from anti-HER2 drugs. This case report describes a young woman with metastatic breast cancer whose tumor was found to carry a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Capecitabine

Share to Carcinoma, Ductal, Breast

Share to Mastectomy

Share to Quinolines

Share to Receptor, ErbB-2

Share to Retreatment

Source

Open in PubMed Open full text

Identifiers

PMID: 26358790
DOI: 10.6004/jnccn.2015.0131
PMCID: PMC4701428

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.PMID 26358790Read ↗

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.Semantic proximity Read ↗

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read ↗

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.Semantic proximity Read ↗

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.Semantic proximity Read ↗

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancerSemantic proximity Read ↗

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerSemantic proximity Read ↗

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies.Semantic proximity Read ↗

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast CancerSemantic proximity Read ↗

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.Semantic proximity Read ↗

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)Semantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.